Neogen's Board of Directors approves a 3-for-2 stock split

Neogen Corporation (Nasdaq: NEOG) today announced that its Board of Directors has approved a 3-for-2 stock split. With the split, shareholders of record on Nov. 30, 2009, will receive one additional share of stock for each two shares held.

The stock split will be effected in the form of a stock dividend that will be paid in newly issued common stock on Dec. 15, 2009. As of today, Neogen has approximately 15,000,000 shares of common stock outstanding. After the stock split, the company will have approximately 22,500,000 shares of common stock outstanding. This is the third stock dividend declared by the company. The most recent was a 3-for-2 split in September 2007.

"We are very pleased to be able to enhance the availability and liquidity of our shares to allow more participation in Neogen's success, while at the same time rewarding our large number of loyal long-term investors," said James Herbert, Neogen's chief executive officer and chairman. "This stock split reflects our Board's strong belief in Neogen's long-term growth, and recognizes a doubling of our stock price during the past year."

All fractional shares resulting from the dividend will be exchanged for cash at the fair market value of Neogen's common stock based on the closing sales price per share on Nov. 30, 2009, as reported on the NASDAQ National Market System.

Stockholders contemplating a transaction of Neogen stock between the record date and payment date should consult a broker regarding entitlement to the dividend shares.

SOURCE Neogen Corporation

Posted in:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.